{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:54:56Z","timestamp":1771512896012,"version":"3.50.1"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.brainres.2025.149946","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:19:51Z","timestamp":1758125991000},"page":"149946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Network meta-analysis of migraine therapies: balancing efficacy and safety"],"prefix":"10.1016","volume":"1867","author":[{"given":"Rajat","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1758-9293","authenticated-orcid":false,"given":"Ayush","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachna","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashank","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.brainres.2025.149946_b0005","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa2035908","article-title":"Atogepant for the preventive treatment of migraine","volume":"385","author":"Ailani","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.brainres.2025.149946_b0010","doi-asserted-by":"crossref","unstructured":"Stephen H. Halpern, M. Joanne Douglas. Appendix: Jadad Scale for Reporting Randomized Controlled Trials. In: Evidence-based Obstetric Anesthesia [Internet]. John Wiley & Sons, Ltd; 2005 [cited 2023 Aug 5]. p. 237\u20138. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/9780470988343.app1.","DOI":"10.1002\/9780470988343.app1"},{"issue":"3","key":"10.1016\/j.brainres.2025.149946_b0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"6","key":"10.1016\/j.brainres.2025.149946_b0020","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1526-4610.2009.01453.x","article-title":"A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine","volume":"49","author":"Aurora","year":"2009","journal-title":"Headache"},{"issue":"4","key":"10.1016\/j.brainres.2025.149946_b0025","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1526-4610.2011.01869.x","article-title":"MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"issue":"12","key":"10.1016\/j.brainres.2025.149946_b0030","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1185\/030079904X15200","article-title":"Effects of a fast disintegrating\/rapid release oral formulation of sumatriptan on functional ability in patients with migraine","volume":"20","author":"Barbanti","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"10.1016\/j.brainres.2025.149946_b0035","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10194-012-0440-y","article-title":"Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial","volume":"13","author":"Barbanti","year":"2012","journal-title":"J. Headache Pain"},{"issue":"9","key":"10.1016\/j.brainres.2025.149946_b0040","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1468-2982.2005.00981.x","article-title":"Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing","volume":"25","author":"Brandes","year":"2005","journal-title":"Cephalalgia Int. J. Headache"},{"key":"#cr-split#-10.1016\/j.brainres.2025.149946_b0045.1","unstructured":"Brar, Y., Hosseini, S.A., Saadabadi, A. 2024. Sumatriptan. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing"},{"key":"#cr-split#-10.1016\/j.brainres.2025.149946_b0045.2","unstructured":"2024 [cited 2024 Sep 27]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470206\/."},{"issue":"6","key":"10.1016\/j.brainres.2025.149946_b0050","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1526-4610.2006.00466.x","article-title":"Efficacy of Rizatriptan 10 mg administered early in a migraine attack","volume":"46","author":"Cady","year":"2006","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.brainres.2025.149946_b0055","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/head.12472","article-title":"A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (the TARGET study)","volume":"55","author":"Cady","year":"2015","journal-title":"Headache"},{"issue":"9","key":"10.1016\/j.brainres.2025.149946_b0060","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2165\/00023210-200317090-00005","article-title":"Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet","volume":"17","author":"Charlesworth","year":"2003","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.brainres.2025.149946_b0065","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1526-4610.2001.041007665.x","article-title":"Efficacy of nonprescription doses of ibuprofen for treating migraine headache. A randomized controlled trial","volume":"41","author":"Codispoti","year":"2001","journal-title":"Headache"},{"issue":"10200","key":"10.1016\/j.brainres.2025.149946_b0070","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"Croop","year":"2019","journal-title":"Lancet Lond. Engl."},{"issue":"10268","key":"10.1016\/j.brainres.2025.149946_b0075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2020","journal-title":"Lancet Lond. Engl."},{"issue":"9","key":"10.1016\/j.brainres.2025.149946_b0080","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/head.14389","article-title":"Zavegepant nasal spray for the acute treatment of migraine: a phase 2\/3 double-blind, randomized, placebo-controlled, dose-ranging trial","volume":"62","author":"Croop","year":"2022","journal-title":"Headache"},{"issue":"10","key":"10.1016\/j.brainres.2025.149946_b0085","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1212\/WNL.57.10.1811","article-title":"Almotriptan Study Group. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine","volume":"57","author":"Dahl\u00f6f","year":"2001","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.brainres.2025.149946_b0090","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.brainres.2025.149946_b0095","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000079544","article-title":"Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms","volume":"52","author":"Diener","year":"2004","journal-title":"Eur. Neurol."},{"issue":"7","key":"10.1016\/j.brainres.2025.149946_b0100","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1526-4610.2005.05151.x","article-title":"Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial","volume":"45","author":"Diener","year":"2005","journal-title":"Headache"},{"issue":"10","key":"10.1016\/j.brainres.2025.149946_b0105","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S1474-4422(15)00198-2","article-title":"New therapeutic approaches for the prevention and treatment of migraine","volume":"14","author":"Diener","year":"2015","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.brainres.2025.149946_b0110","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/0333102409359314","article-title":"Czech migraine investigators group. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study","volume":"30","author":"Djupesland","year":"2010","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"Suppl 1","key":"10.1016\/j.brainres.2025.149946_b0115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/head.13300","article-title":"A phase-by-phase review of migraine pathophysiology","volume":"58","author":"Dodick","year":"2018","journal-title":"Headache"},{"issue":"6","key":"10.1016\/j.brainres.2025.149946_b0120","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"2","key":"10.1016\/j.brainres.2025.149946_b0125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/00023210-200519020-00003","article-title":"Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study","volume":"19","author":"Dodick","year":"2005","journal-title":"CNS Drugs"},{"issue":"19","key":"10.1016\/j.brainres.2025.149946_b0130","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"J. Am. Med. Assoc."},{"issue":"23","key":"10.1016\/j.brainres.2025.149946_b9000","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","article-title":"Ubrogepant for the Treatment of Migraine","volume":"381","author":"Dodick","year":"2019","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.brainres.2025.149946_b0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1468-2982.2002.00319.x","article-title":"Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine","volume":"22","author":"Dowson","year":"2002","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"4","key":"10.1016\/j.brainres.2025.149946_b0140","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1526-4610.2004.04074.x","article-title":"Almotriptan improves response rates when treatment is within 1 hour of migraine onset","volume":"44","author":"Dowson","year":"2004","journal-title":"Headache"},{"issue":"6","key":"10.1016\/j.brainres.2025.149946_b0145","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1046\/j.1468-2982.2002.00372.x","article-title":"Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs","volume":"22","author":"Eletriptan Steering Committee in Japan","year":"2002","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"6","key":"10.1016\/j.brainres.2025.149946_b0150","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1468-2982.2003.00554.x","article-title":"Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan","volume":"23","author":"F\u00e4rkkil\u00e4","year":"2003","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"5","key":"10.1016\/j.brainres.2025.149946_b0155","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(12)70047-9","article-title":"Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study","volume":"11","author":"F\u00e4rkkil\u00e4","year":"2012","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.brainres.2025.149946_b9005","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1177\/0333102410375512","article-title":"Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan\u2013a randomised proof-of-concept trial","volume":"30","author":"Ferrari","year":"2010","journal-title":"Cephalalgia."},{"issue":"6","key":"10.1016\/j.brainres.2025.149946_b0160","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2007.01053.x","article-title":"Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment","volume":"48","author":"Freitag","year":"2008","journal-title":"Headache"},{"issue":"9","key":"10.1016\/j.brainres.2025.149946_b0165","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1046\/j.1468-2982.2003.00593.x","article-title":"Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine","volume":"23","author":"Garcia-Ramos","year":"2003","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"1","key":"10.1016\/j.brainres.2025.149946_b0170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1526-4610.2005.05004.x","article-title":"Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine\u2013results from phase 1 of the REALIZE Study","volume":"45","author":"Gawel","year":"2005","journal-title":"Headache"},{"issue":"9995","key":"10.1016\/j.brainres.2025.149946_b0175","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Global Burden of Disease Study 2013 Collaborators","year":"2015","journal-title":"Lancet Lond Engl."},{"issue":"1","key":"10.1016\/j.brainres.2025.149946_b0180","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1212\/WNL.54.1.156","article-title":"Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan steering committee","volume":"54","author":"Goadsby","year":"2000","journal-title":"Neurology."},{"issue":"4","key":"10.1016\/j.brainres.2025.149946_b0185","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1468-2982.2008.01546.x","article-title":"Early vs. non-early intervention in acute migraine-\u2019Act when Mild (AwM)\u2019. A double-blind, placebo-controlled trial of almotriptan","volume":"28","author":"Goadsby","year":"2008","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"22","key":"10.1016\/j.brainres.2025.149946_b0190","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.brainres.2025.149946_b0195","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain J. Neurol."},{"issue":"9","key":"10.1016\/j.brainres.2025.149946_b0200","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","article-title":"Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial","volume":"19","author":"Goadsby","year":"2020","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.brainres.2025.149946_b0205","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/j.1526-4610.2012.02198.x","article-title":"A sumatriptan iontophoretic transdermal system for the acute treatment of migraine","volume":"52","author":"Goldstein","year":"2012","journal-title":"Headache"},{"issue":"8","key":"10.1016\/j.brainres.2025.149946_b0210","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0149-2918(00)80068-5","article-title":"Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 study group","volume":"22","author":"Havanka","year":"2000","journal-title":"Clin. Ther."},{"issue":"9","key":"10.1016\/j.brainres.2025.149946_b0215","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0333102413485658","article-title":"The international classification of headache disorders, 3rd edition (beta version)","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"16","key":"10.1016\/j.brainres.2025.149946_b0220","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1212\/01.WNL.0000286940.29755.61","article-title":"Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine","volume":"70","author":"Ho","year":"2008","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.brainres.2025.149946_b0225","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.brainres.2025.149946_b0230","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S031716710000473X","article-title":"Pain free efficacy of sumatriptan in the early treatment of migraine","volume":"33","author":"Jelinski","year":"2006","journal-title":"Can. J. Neurol. Sci. J. Can. Sci. Neurol."},{"issue":"4","key":"10.1016\/j.brainres.2025.149946_b0235","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1468-2982.2000.00055.x","article-title":"Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"20","author":"Kellstein","year":"2000","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"11","key":"10.1016\/j.brainres.2025.149946_b0240","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1468-2982.2004.00735.x","article-title":"ZODIAC study group. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild","volume":"24","author":"Klapper","year":"2004","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"5","key":"10.1016\/j.brainres.2025.149946_b0245","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1023\/A:1007559003261","article-title":"Spreading depression-induced cyclooxygenase-2 expression in the cortex","volume":"25","author":"Koistinaho","year":"2000","journal-title":"Neurochem. Res."},{"issue":"24","key":"10.1016\/j.brainres.2025.149946_b0250","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.brainres.2025.149946_b0255","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1368-5031.2004.00295.x","article-title":"Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine","volume":"58","author":"Landy","year":"2004","journal-title":"Int. J. Clin. Pract."},{"issue":"7","key":"10.1016\/j.brainres.2025.149946_b0260","first-page":"663","article-title":"Acetylsalicylic acid effervescent 1000 mg (Aspirin) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study","volume":"20","author":"Lange","year":"2000","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"Pt 1","key":"10.1016\/j.brainres.2025.149946_b0265","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/brain\/117.1.199","article-title":"Pathophysiology of the migraine aura. The spreading depression theory","volume":"117","author":"Lauritzen","year":"1994","journal-title":"Brain J. Neurol."},{"issue":"6","key":"10.1016\/j.brainres.2025.149946_b0270","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1152\/jn.1947.10.6.409","article-title":"Further observations on the spreading depression of activity in the cerebral cortex","volume":"10","author":"Leao","year":"1947","journal-title":"J. Neurophysiol."},{"issue":"5","key":"10.1016\/j.brainres.2025.149946_b0275","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/head.13309","article-title":"DFN-02 (Sumatriptan 10 mg with a permeation enhancer) nasal spray vs placebo in the acute treatment of migraine: a double-blind, Placebo-controlled study","volume":"58","author":"Lipton","year":"2018","journal-title":"Headache"},{"issue":"2","key":"10.1016\/j.brainres.2025.149946_b0280","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1811090","article-title":"Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine","volume":"381","author":"Lipton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.brainres.2025.149946_b0285","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial","volume":"322","author":"Lipton","year":"2019","journal-title":"J. Am. Med. Assoc."},{"issue":"3","key":"10.1016\/j.brainres.2025.149946_b0290","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","article-title":"Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial","volume":"22","author":"Lipton","year":"2023","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.brainres.2025.149946_b0295","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1185\/030079905X28926","article-title":"Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo- controlled trial","volume":"21","author":"Loder","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"10.1016\/j.brainres.2025.149946_b0300","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1468-2982.2007.01313.x","article-title":"Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies","volume":"27","author":"Mannix","year":"2007","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"14","key":"10.1016\/j.brainres.2025.149946_b0305","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1177\/0333102420949173","article-title":"Vascular actions of peripheral CGRP in migraine-like photophobia in mice","volume":"40","author":"Mason","year":"2020","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"2","key":"10.1016\/j.brainres.2025.149946_b0310","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1526-4610.2006.00686.x","article-title":"Early intervention with almotriptan: results of the AEGIS trial (AXERT early migraine intervention study)","volume":"47","author":"Mathew","year":"2007","journal-title":"Headache"},{"issue":"14","key":"10.1016\/j.brainres.2025.149946_b0315","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"21","author":"Methley","year":"2014","journal-title":"BMC Health Serv. Res."},{"issue":"12","key":"10.1016\/j.brainres.2025.149946_b0320","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.94.12.6500","article-title":"Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2","volume":"94","author":"Miettinen","year":"1997","journal-title":"PNAS"},{"issue":"950","key":"10.1016\/j.brainres.2025.149946_b0325","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/pgmj.2003.012393","article-title":"Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial","volume":"80","author":"Misra","year":"2004","journal-title":"Postgrad. Med. J."},{"issue":"10","key":"10.1016\/j.brainres.2025.149946_b0330","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.brainres.2025.149946_b0335","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/13543784.2012.681044","article-title":"CGRP receptor antagonists: an expanding drug class for acute migraine?","volume":"21","author":"Negro","year":"2012","journal-title":"Expert Opin. Invest. Drugs"},{"key":"#cr-split#-10.1016\/j.brainres.2025.149946_b0340.1","unstructured":"Nicolas, S., Nicolas, D. 2024. Triptans. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing"},{"key":"#cr-split#-10.1016\/j.brainres.2025.149946_b0340.2","unstructured":"2024 [cited 2024 Sep 27]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554507\/."},{"issue":"6","key":"10.1016\/j.brainres.2025.149946_b0345","first-page":"1966","article-title":"NSAIDs in the acute treatment of migraine: a review of clinical and experimental data","volume":"3","author":"Pardutz","year":"2010","journal-title":"Pharm. Basel Switz."},{"issue":"6","key":"10.1016\/j.brainres.2025.149946_b0350","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1468-2982.2000.00091.x","article-title":"Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study","volume":"20","author":"Pascual","year":"2000","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"5","key":"10.1016\/j.brainres.2025.149946_b0355","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1468-2982.2000.00069.x","article-title":"Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan study group","volume":"20","author":"Pascual","year":"2000","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"2","key":"10.1016\/j.brainres.2025.149946_b0360","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/head.12767","article-title":"A Randomized trial of ketorolac vs. sumatripan vs. placebo nasal spray (KSPN) for acute migraine","volume":"56","author":"Rao","year":"2016","journal-title":"Headache"},{"issue":"Suppl 2","key":"10.1016\/j.brainres.2025.149946_b0365","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1046\/j.1526-4610.42.s2.5.x","article-title":"Dose range-finding studies with frovatriptan in the acute treatment of migraine","volume":"42","author":"Rapoport","year":"2002","journal-title":"Headache"},{"key":"#cr-split#-10.1016\/j.brainres.2025.149946_b0370.1","unstructured":"Rashid, A., Manghi, A. 2024. Calcitonin Gene-Related Peptide Receptor. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing"},{"key":"#cr-split#-10.1016\/j.brainres.2025.149946_b0370.2","unstructured":"2024 [cited 2024 Sep 27]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560648\/."},{"issue":"10161","key":"10.1016\/j.brainres.2025.149946_b0375","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet Lond Engl."},{"issue":"1","key":"10.1016\/j.brainres.2025.149946_b0380","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1526-4610.2006.00313.x","article-title":"Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents","volume":"46","author":"Rothner","year":"2006","journal-title":"Headache"},{"issue":"4","key":"10.1016\/j.brainres.2025.149946_b0385","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","article-title":"Calcitonin gene-related peptide: physiology and pathophysiology","volume":"94","author":"Russell","year":"2014","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.brainres.2025.149946_b0390","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00023210-200013030-00007","article-title":"Efficacy of Zolmitriptan at early time-points for the acute treatment of migraine and treatment of recurrence","volume":"13","author":"Ryan","year":"2000","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.brainres.2025.149946_b0395","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1468-2982.2002.00377.x","article-title":"Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose-response study","volume":"22","author":"Sakai","year":"2002","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"7","key":"10.1016\/j.brainres.2025.149946_b0400","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/head.14169","article-title":"Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients","volume":"61","author":"Sakai","year":"2021","journal-title":"Headache"},{"issue":"8","key":"10.1016\/j.brainres.2025.149946_b0405","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/WNL.59.8.1210","article-title":"Eletriptan Steering Committee. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study","volume":"59","author":"Sandrini","year":"2002","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.brainres.2025.149946_b0410","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.clinthera.2005.04.003","article-title":"Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating\/rapid-release formulation of sumatriptan tablets","volume":"27","author":"Sheftell","year":"2005","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.brainres.2025.149946_b0415","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1526-4610.2003.03043.x","article-title":"Eletriptan Steering Committee. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States","volume":"43","author":"Sheftell","year":"2003","journal-title":"Headache"},{"issue":"22","key":"10.1016\/j.brainres.2025.149946_b0420","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.brainres.2025.149946_b0425","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaneurol.2017.3859","article-title":"Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial","volume":"75","author":"Skljarevski","year":"2018","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.brainres.2025.149946_b0430","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"2","key":"10.1016\/j.brainres.2025.149946_b0435","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/0333102417737765","article-title":"Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine","volume":"38","author":"Spierings","year":"2018","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"15","key":"10.1016\/j.brainres.2025.149946_b0440","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2165\/00023210-200418150-00007","article-title":"Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet","volume":"18","author":"Spierings","year":"2004","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.brainres.2025.149946_b0445","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1468-2982.2002.00300.x","article-title":"Eletriptan Steering Committee. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks","volume":"22","author":"Stark","year":"2002","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"3","key":"10.1016\/j.brainres.2025.149946_b0450","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1468-2982.2007.01288.x","article-title":"The global burden of headache: a documentation of headache prevalence and disability worldwide","volume":"27","author":"Stovner","year":"2007","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"6","key":"10.1016\/j.brainres.2025.149946_b0455","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/head.14138","article-title":"Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study","volume":"61","author":"Takeshima","year":"2021","journal-title":"Headache"},{"issue":"6","key":"10.1016\/j.brainres.2025.149946_b0460","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10194-006-0333-z","article-title":"Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study","volume":"7","author":"Tfelt-Hansen","year":"2006","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.brainres.2025.149946_b0465","article-title":"From A to E: uniting vitamins against stroke risk-a systematic review and network meta-analysis","volume":"30","author":"Tripathi","year":"2024","journal-title":"Eur. J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.brainres.2025.149946_b0470","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/0333102416653233","article-title":"A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine","volume":"36","author":"Voss","year":"2016","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"2","key":"10.1016\/j.brainres.2025.149946_b0475","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1726-4901(09)70300-4","article-title":"Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine","volume":"70","author":"Wang","year":"2007","journal-title":"J. Chin. Med. Assoc. JCMA"},{"issue":"13","key":"10.1016\/j.brainres.2025.149946_b0480","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1177\/03331024211024160","article-title":"Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: the EMPOwER study","volume":"41","author":"Wang","year":"2021","journal-title":"Cephalalgia Int. J. Headache"},{"issue":"4","key":"10.1016\/j.brainres.2025.149946_b0485","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.clinthera.2006.03.013","article-title":"A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults","volume":"28","author":"Wendt","year":"2006","journal-title":"Clin. Ther."},{"issue":"10","key":"10.1016\/j.brainres.2025.149946_b0490","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.4065\/78.10.1214","article-title":"Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies","volume":"78","author":"Winner","year":"2003","journal-title":"Mayo Clin. Proc."}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899325005098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899325005098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T09:25:05Z","timestamp":1764581105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899325005098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":103,"alternative-id":["S0006899325005098"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2025.149946","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Network meta-analysis of migraine therapies: balancing efficacy and safety","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2025.149946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"149946"}}